Globus Medical (GMED) to Release Quarterly Earnings on Tuesday

Globus Medical (NYSE:GMEDGet Free Report) is set to announce its earnings results after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of $0.58 per share for the quarter.

Globus Medical Trading Down 0.1 %

NYSE GMED opened at $52.29 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.36 and a current ratio of 4.47. The company has a market capitalization of $7.21 billion, a price-to-earnings ratio of 33.74, a price-to-earnings-growth ratio of 1.73 and a beta of 1.10. The company’s 50-day simple moving average is $52.53 and its two-hundred day simple moving average is $51.58. Globus Medical has a one year low of $43.38 and a one year high of $62.88.

Institutional Trading of Globus Medical

Institutional investors have recently bought and sold shares of the stock. Bayesian Capital Management LP acquired a new stake in Globus Medical during the 1st quarter valued at approximately $230,000. Hudson Bay Capital Management LP acquired a new stake in Globus Medical during the 1st quarter valued at approximately $219,000. MML Investors Services LLC acquired a new stake in Globus Medical during the 2nd quarter valued at approximately $218,000. Mercer Global Advisors Inc. ADV acquired a new stake in Globus Medical during the 3rd quarter valued at approximately $209,000. Finally, Pearl River Capital LLC acquired a new stake in Globus Medical during the 1st quarter valued at approximately $205,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Morgan Stanley cut their target price on shares of Globus Medical from $60.00 to $53.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 14th. Canaccord Genuity Group raised their target price on shares of Globus Medical from $67.00 to $71.00 and gave the company a “buy” rating in a research report on Wednesday, December 20th. Truist Financial lifted their price objective on shares of Globus Medical from $53.00 to $58.00 and gave the stock a “hold” rating in a research report on Friday, December 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Globus Medical in a research report on Thursday, January 11th. Finally, Roth Mkm began coverage on shares of Globus Medical in a research report on Friday, October 20th. They issued a “buy” rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $66.11.

Read Our Latest Stock Report on Globus Medical

Globus Medical Company Profile

(Get Free Report)

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.

Read More

Earnings History for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.